CC
SUPN icon

Centiva Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Centiva Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,108
Closed -$331K – 2075
2025
Q1 		$331K Buy
10,108
+957
+10% +$33.9K 0.02% 1029
2024
Q4 		$331K Buy
+9,151
New +$322K 0.01% 1070
2024
Q3 		– Sell
-11,719
Closed -$313K – 2606
2024
Q2 		$313K Buy
+11,719
New +$340K 0.02% 1432
2024
Q1 		– Sell
-8,538
Closed -$247K – 2278
2023
Q4 		$247K Buy
+8,538
New +$226K 0.02% 1310
2023
Q2 		– Sell
-6,977
Closed -$253K – 2007
2023
Q1 		$253K Buy
+6,977
New +$268K 0.01% 1133
2020
Q2 		– Sell
-11,485
Closed -$207K – 824
2020
Q1 		$207K Buy
+11,485
New +$241K 0.03% 440

Other funds holding SUPN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return